| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9905249 | Cancer Letters | 2005 | 9 Pages |
Abstract
The implications of these findings are discussed with focus on the potentials and limitations of introducing 1H-MRS for clinical assessment of treatment response in children with neuroblastoma. Biochemical monitoring of neuroblastoma with 1H-MRS could enable tailoring of individual therapy as well as provide early pharmacodynamic evaluation of novel therapeutic modalities.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Magnus Lindskog, Christian Spenger, Tomas Klason, Jüri Jarvet, Astrid Gräslund, John Inge Johnsen, Frida Ponthan, Lena Douglas, Bo Nordell, Per Kogner,